Yale University

In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.

Yale University

Academic Research

Quick Facts

Sponsored Trials

Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain

Psilocybin Microdosing on Cognition, Mood and Quality of Life

MDMA in Borderline Personality Disorder (MDMA in BPD)

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

PCORI Comparative Effectiveness Study-Esketamine (Spravato) Vs. Ketamine-Equivalence Study

Psychedelic Virtual Reality

Mechanistic Studies of Psilocybin in Headache Disorders

Open-Label Psilocybin

Role Of Non-Specific Effects in The Treatment of Depression With Esketamine (ROSETTE)

The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)

Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment

The OBSERVE Protocol

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

Long Term Follow Up KET-PD

Enhancing Week-long Psychological Treatment for PTSD With Ketamine

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

Effects of Repeated Psilocybin Dosing in OCD

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

Ketamine for the Treatment of Depression in Parkinson's Disease

Repeat Dosing of Psilocybin in Migraine Headache

Collaborated Trials

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

Company

Product

Legal